Description du projet
Vers une production pharmaceutique européenne de principes actifs plus durable
Les produits pharmaceutiques comprennent une grande variété de composés chimiques conçus pour garantir des traitements sûrs et efficaces. Les principes actifs sont les ingrédients qui produisent les effets bénéfiques sur la santé des patients. L’objectif du projet TransPharm, financé par l’UE, est de développer des principes actifs plus durables et plus écologiques qui réduisent simultanément l’empreinte environnementale et la dépendance vis-à-vis des pays tiers pour leur production. TransPharm fournira des outils numériques et des lignes directrices fondés sur l’intelligence artificielle pour le développement de produits pharmaceutiques et de principes actifs plus écologiques, ainsi que des modèles permettant d’évaluer leur impact. Il en résultera une industrie pharmaceutique européenne plus indépendante et plus compétitive, capable de fournir en temps voulu des produits thérapeutiques durables et écologiques à ses citoyens.
Objectif
TransPharm two-track approach focusses on the one hand on the compounds itself by identifying greener and more sustainable-by-design Active Pharmaceutical Ingredients (APIs) and on the other hand reducing the environmental impact and resilience of the manufacturing process by optimizing the synthesis route of new APIs in continuous flow and by proposing greener alternative solvents.
The aim of the project is to (i) analyse and predict flow behaviour and environmental biodegradability of APIs and their synthesis pathways; (ii) identify greener and more sustainable alternatives to pharmaceutical products / APIs of concern; (iii) reduce the footprint and create important shortcuts in synthetic schemes of APIs; and (iv) assess the sustainability of pharmaceuticals over their entire life cycle. To reach the envisaged aims, the project will deliver four toolboxes (consisting of digital tools and guidelines) for the development of greener pharmaceutical products and APIs. These toolboxes will be used to (v) assess the potential to move towards the transition to greener, more agile pharmaceutical production. In addition, TransPharm will elaborate on the business case for sustainable pharmaceutical products or APIs and what is needed to bring them to the market. The project will also make sure that (vi) key project results and knowledge are properly transferred towards targeted stakeholders.
TransPharm?s outcome contribute to a Europe, that is self-sufficient by reducing dependence on API production in third countries; making the EU healthcare industry more competitive, sustainable and reliable, ensuring timely supply of essential medicines from particularly complex or critical supply and distribution chains and positioning EU as a leader in innovative technologies.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- social scienceseconomics and businessbusiness and managementbusiness models
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- social scienceseconomics and businesseconomicssustainable economy
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
9000 Gent
Belgique